

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMERCE OF PATENTS AND TRADEMARKS
WWW 984 mgtor 10 of 2000 (1)
www.supple.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/658,835 09/08/2000 Jonathan P. Duvick H34R 2865

27142 7590 03 26 2002

MCKEE, VOORHEES & SEASE, P.L.C. ATTN: PIONEER HI-BRED 801 GRAND AVENUE, SUITE 3200 DES MOINES, IA 50309-2721 EXAMINER

IBRAHIM, MEDINA AHMED

ARTUNIT PAPER NUMBER

1638

DATE MAILED: 03-26-2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED TES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/658, 835	09/08/2000	Jonathan Duvick	1134R

EXAMINER				
Medina A. Ibrahim				
ART UNIT	PAPER NUMBER			
1638	9			
DATE MAILED:				

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Medina A. Ibrahim, Art Unit 1638, whose telephone number is (703)306-5822.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

ESX7MCL GIRO THE CLOUMIN POTEMY EXTRAGARA THEIR 1600

Application No.: 09/658, 835

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
Ø	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged
	computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
Ар	plicant Must Provide:
X	Attained or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	Aminitial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
	r Rules Interpretation, call (703) 308-4216
	r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA)
гa	Technical Assistance703-287-0200
	To Purchase PatentIn Software703-306-2600

FORM **PTO-1472** (Rev. 3-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

EXAMINER'S CASE ACTION WORKSHEET

Application No. 09/658, 835		Legal Instrument Examiner		
CHECK TYPE OF ACTION DATE OF COUNT				
Non-Final Rejection	Restriction/ Election Only	Final Rejection		
Ex Parte Quayle	☐ Allowance	Advisory Action		
Examiner's Answer (Including Supplemental)	Reply Brief Noted	Non-Entry of Reply Brief		
Notice of Defective Appeal Brief	Interference SPE Approval for Disposal	Suspension SPE (Initial)		
Allowance After Examiner's Answer	SIR Disposal (use only after FAOM)	Post-Allowance Communication		
Miscellaneous Office Letter (With Shortened Statutory Period Set)	Notice of Non-Responsive Amendment (With One Month Time Limit Set)	Miscellaneous Office Letter (No Response Period Set)		
Letter Requiring Formal Drawings	Supplemental Action	Response to a Rule 312 Amendment		
Restart Time Period (e.g., Missing References)	☐ Interview Summary	Authorization to Change Previous Office Action SPE (Initial)		
Abandonment	Express Abandonment Date:	Abandonment After Examiner's Answer		
Examiner's Name:	Medina A. Ibrahim	GAU: 1638		